Nextremity Solutions, Inc. is a privately held medical device company focused exclusively on foot and ankle surgical interventions. Its current product portfolio includes the Nextra® Hammertoe Correction System, the Re+Line® Bunion Correction System, and the MSPTM Metatarsal Shortening System. The company markets procedure-ready, sterile implant systems built on proprietary technology intended to deliver repeatable and superior clinical outcomes. Nextremity says it plans to greatly expand its product portfolio and to release 10 product systems in 2015–2016. It also intends to provide additional educational opportunities to foster surgeon-to-surgeon relationships. In May 2015 the company reported an oversubscribed preferred stock offering that the company says positions it to execute its planned objectives and accelerate growth. Nextremity Solutions develops orthopaedic devices concentrated on the foot and ankle segment, with offices in Red Bank, NJ and Warsaw, IN. The company was founded by two orthopaedic surgeons, Lon Weiner MD and Stuart Katchis MD, and emphasizes surgical principles of compression, stability, repeatability and predictability. Its flagship product is the Nextra interbody fusion device for hammertoe correction, described as the only two-piece metallic fully reversible implant of its kind. Nextremity has gained market acceptance for that product and continues to expand its existing product portfolio. Management says the company will use new capital to accelerate growth of current products and to fuel its product pipeline. The Board of Directors and shareholders approved the recent financing.

Total raised

$13M

Funding rounds

2

Latest round

Preferred

Latest activity

May 2015